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Abstract
Azole drugs such as econazole, are active on Mycobacterium tuberculosis and Mycobacterium smegmatis; however, the iden-
tification of their target(s) is still pending. It has been reported that mutations in the non- essential system mmpL5- mmpS5 
conferred resistance to econazole in M. tuberculosis. We herein report that an azole- resistant mutant screen in M. smegmatis 
rendered mutations in rshA, encoding a non- essential anti- sigma H protein.
Mycobacterium tuberculosis, the causative agent of tubercu-
losis, is still one of the three major infectious agents leading 
to death of more than 1.5 million people and 10 million new 
cases per year [1]. The treatment of tuberculosis is lengthy 
and cumbersome, requiring from six to 24 months, and is 
currently jeopardized by the rise of drug- resistant strains that 
are refractory to most if not all the known available drugs 
[2]. Those facts underscore the need for novel therapeutic 
strategies; however in the last 10 years few additions to the 
therapeutic portfolio have been made [3].
The polycyclic azoles are Cytochrome (Cyt) P450 inhibitors, 
which have been used in the treatment of fungal pathogens, 
on which they are active by inhibition of Cytochrome P450 
(Cyp)51, an essential lanosterol 14α–demethylase, involved 
in the synthesis of the cell membrane component ergosterol 
[4]. Interestingly, the members of the genus Mycobacterium 
contains a large array of Cyps, while the M. tuberculosis 
genome encodes 20 Cyps, Mycobacterium bovis has 18 
and M. smegmatis has 39 of them [5, 6]. The essentiality of 
several of these genes was examined due to the interest Cyps 
represent as drug targets [7, 8]. Importantly activity of azoles 
on M. tuberculosis (in vitro, ex vivo and in a murine model) 
and M. smegmatis has been described [9–12], fostering the 
attention to the identification of their targets. Of note, myco-
bacteria does not contain ergosterol in their cell- membrane 
composition and do not synthesize sterols [13, 14], pointing 
to a novel mechanism of action of azole drugs in these bacteria 
different to that taking place in fungi. Disappointingly, trans-
poson saturation mutagenesis technologies have shown that 
only cyp136 (encoded by Rv3059) confers an in vitro growth 
advantage while none of the remaining members of the Cyp 
mycobacterial repertoire was essential [15]. More puzzlingly, 
deletion of cyp125, although not essential, caused a tenfold 
increase in the susceptibility of M. tuberculosis to econazole 
(Eco) [16]; thus none of the CYPs fulfilled the criteria for 
being considered a target for azoles, although there is a large 
body of information on binding of those drugs to CYPs 
[17–20]. Moreover, we have previously demonstrated that 
imidazoles are bactericidal to M. tuberculosis, and that they 
generate a large increase in reactive oxygen species (ROS) 
[16]. However, that event is not related to the mechanism 
of killing of azoles since over- expression of sodC or katG, 
enzymes detoxifying oxygen radicals in M. tuberculosis, had 
no effect on the susceptibility to those compounds. Adding 
complexity to the scenario, it was also found that Eco treat-
ment of wild- type and an Eco- resistant M. tuberculosis mutant 
brought about comparable changes in carbohydrates, amino 
acids and energy metabolism suggesting that stress adapta-
tion may play a role in the resistance to this compound 
[16]. Until now, only one mechanism of resistance has been 
genetically demonstrated in M. tuberculosis, consisting in the 
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up- regulation of the efflux pump system encoded by mmpS5–
mmpL5 genes due to mutations either in the Rv0678 gene, 
involved in the transcriptional regulation of this efflux system, 
or in its putative promoter/operator region [21]. In a recent 
review, Briffotaux et al. analysed the role of MmpL5- MmpS5 
as an efflux pump in Mycobacterium species [22]. MmpL5- 
MmpS5 are present in all mycobacterial species except for 
M. leprae, differing in the nature of the transcriptional regu-
lator; while M. tuberculosis and other slow growers contain a 
MarR transcriptional regulator, fast- growing species such as 
M. smegmatis have a transcriptional regulator belonging to 
the TetR family [22]. The fact that it was demonstrated that 
Rv0678 binds ‘in vitro’ not only the mmpL5- mmpS5 promoter 
but also those of mmpL4- mmpL4 and mmpL2- mmpS2 raises 
a question on other effects that this mechanism of Eco resist-
ance may have in M. tuberculosis [22]. So far, in spite of the 
identification of the MmpL5- MmpS5 system as the only 
genes reported as related to resistance to azole drugs in M. 
tuberculosis, the identity of the target(s) for those drugs in this 
pathogen remains elusive.
We hypothesized that the use of M. smegmatis, a sapro-
phytic species with an ample range of growth temperatures 
that allows for the isolation of temperature- sensitive (Ts) 
mutants – thus indicative of mutations causing loss of func-
tion in essential genes – would allow for the identification 
of a candidate target for azole drugs. A similar strategy was 
successfully carried out by Vilchéze et al., leading to the iden-
tification of InhA – target for the first- line anti- tubercular 
drug isoniazid – in M. smegmatis [23]. To that aim, we first 
examined the influence of medium composition on econazole 
activity. The reports on MIC99 values for Eco and clotrimazole 
(Clo) on M. smegmatis widely vary depending on the culture 
medium and methodology used and are specially low in 
complex medium such as LB (MIC99=2 µg ml
−1 and 0.5 µg 
ml−1, respectively [10]) when compared to chemically defined 
medium such as Sauton medium (MIC99=20 µg ml
−1 and 15 
µg ml−1, respectively [10]. Eco and Clo inhibit M. tubercu-
losis on solid Middlebrook 7H11ADS glycerol agar medium 
(MIC99=8 µg ml
−1 in both cases [21]) or Middlebrook 7H9 
ADS glycerol (7H9 ADS Gly for short) broth (MIC99=15 µg 
ml−1 and 17 µg ml−1, respectively [24]. Thus, in order to choose 
a growth medium for our screening, we analysed the influence 
of its composition on azole activity on M. smegmatis. In our 
hands Eco and Clo inhibited M. smegmatis with comparable 
efficacy on Middlebrook 7H9 ADS Gly agar plates (MIC99=15 
µg ml−1 and 12 µg ml−1, respectively) and Mueller–Hinton agar 
plates (MIC99=1.0 µg ml
−1 and 0.5 µg ml−1). Interestingly, while 
assessing the influence that the different components of the 
growth medium could have on Eco activity, we found that the 
addition of dextrose (0.4 % w/v) resulted in a twofold increase 
in the MIC99Eco in Mueller–Hinton agar and LB agar media 
for the wild- type strain M. smegmatis mc2155. Conversely, 
using a reconstitution approach to a ‘basal’ Middlebrook 
7H9 ClNa agar medium, we noticed that Eco was much 
more active when 0.5 % (w/v) glycerol was the carbon source 
(MIC99=2 µg ml
−1); this value did not change upon addition of 
other components present in LB [0.2 % (w/v) yeast extract or 
0.1 % (w/v) casaminoacids]. In contrast, the presence of 0.4 % 
(w/v) dextrose as the carbon source increased resistance to 
Eco (MIC99 Eco=10 µg ml
−1) yielding small size colonies but 
in comparable numbers to those on control plates up to that 
concentration. Since the reported MIC for M. tuberculosis 
when Middlebrook 7H11 ADS- Gly (thus, containing both 
dextrose and glycerol), Sauton or Youngman liquid media 
(both containing only glycerol as the carbon source) are used 
ranges from 8 to 20 µg ml−1 as cited above, we hypothesized 
that other components present in those three growth media 
could also be influencing the activity of the drug; thus we 
tested Zn2+ (10–50 µg ml−1) addition of which consistently 
helped M. smegmatis to grow in Mueller–Hinton agar and 
LB agar containing Eco 5 µg ml−1; however growth was again 
comparable to control plates in colony numbers but smaller 
in size especially at the higher concentration. The addition 
of this cation to Middlebrook 7H9 dextrose caused only 
a marginal but reproducible increase in the MIC (MIC99 
Eco=12–15 µg ml−1). The activity of Clo was equally affected 
by growth medium composition (data not shown). Taken as a 
whole, our findings explain the reported differences on azole 
activity on mycobacteria as the nature of the growth medium 
clearly influence the susceptibility to those drugs.
On the rationale that the ability of M. smegmatis to grow 
at a wide range of temperatures would allow obtaining 
temperature- sensitive (Ts) mutants affected in essential path-
ways linked to resistance to azoles, we next set to isolate Ts 
Eco- and Clo- resistant mutants in M. smegmatis [using each 
time five independent cultures grown at 30 °C from a small 
inoculum ≈105 c.f.u. ml−1 by plating aliquots (107–109 c.f.u.) 
on 7H9ADSGly agar plates (chosen in order to be compa-
rable to previously reported M. tuberculosis mutant- selection 
medium [21]) containing 50 µg ml−1 of Eco or Clo]; however 
this strategy failed as none of the obtained azole- resistant 
mutants displayed a Ts phenotype in spite of several attempts. 
Notwithstanding this, we obtained several M. smegmatis 
non- Ts mutants resistant to Eco and Clo (frequency of isola-
tion ~4×10−8). MIC values for those mutants were of two–
fivefold MIC (30–75 µg ml−1) for Eco and two–threefold MIC 
(30–40 µg ml−1) for Clo. A set of four mutants was further 
characterized on the basis of phenotypic differences such as 
colony morphology and sliding motility (indicative of cell- 
wall alterations), generation time and level of resistance to 
azoles. While the morphology of the colonies and duplication 
times of mutants Eco- R1, Eco- R2 and Eco- R8 were compa-
rable to those of the parental strain; mutant Eco- R6 showed 
a much longer duplication time (4.6 h) (Fig. 1). Interestingly, 
mutants differed in their MIC Eco in MH agar plates, while 
mutants Eco- R1 and Eco- R2 were resistant to 4 µg ml−1, 
mutants Eco- R6 and Eco- R8 were resistant to 16 µg ml−1 and 
32 µg ml−1, respectively. Although mutant Eco- R2 displayed 
a smooth colony morphology and higher Congo red binding 
than the other mutants, we hypothesized that mutations 
increasing the dispensable synthesis of glycopeptidolipids 
(known to be inhibited by azoles [10]) would explain that 
morphotype.
3
Morbidoni et al., Access Microbiology 2019
As mentioned above, Milano et al. reported that isolated 
spontaneous M. tuberculosis and M. bovis BCG mutants 
resistant to azoles had mutations in the transcriptional 
regulator Rv0678, which led to increased transcription of the 
Rv0677c and Rv0676c genes corresponding to the proteins 
MmpS5 and MmpL5, which conform a hypothetical efflux 
system belonging to the resistance–nodulation–division 
(RND) family of transporters [21]; those proteins have also 
been shown to play a role in resistance to bedaquiline and 
clofazimine in M. tuberculosis [25]. Of note, the efflux pump 
inhibitors (EPIs) reserpine and verapamil were able to increase 
the susceptibility to those drugs in wild- type and resistant 
mutants at low concentrations [25]. Thus, we determined 
the effect of the addition of sub- inhibitory concentrations of 
reserpine (12 µg ml−1) or verapamil (40 µg ml−1) on the activity 
of Eco and Clo in the parental M. smegmatis strain; our results 
showed that the addition of those EPIs failed to allow for 
growth in the presence of Eco at 37 °C (Fig. 2); comparable 
results were observed when Clo was used (data not shown); 
however M. smegmatis EcoR mutants 1, 2, 6 and 8 were able to 
grow in the presence of Eco at 50 µg ml−1 even when reserpine 
and verapamil were added, indicating a lack of effect of both 
EPIs on the resistance phenotype of those mutants (Fig. 2, 
only mutant Eco- R8 is shown by the sake of simplicity). 
Susceptibility of the mutants to several compounds (isoni-
azid, ethionamide, erythromycin, tetracycline, novobiocin 
and streptomycin) was comparable to that of the wild- type 
strain, while only chloramphenicol revealed differences in 
susceptibility with an eightfold increase in the mutants vs the 
parental strain (MIC=64 µg ml−1 and 8 µg ml−1, respectively, 
data not shown).
We next set to determine the presence of mutations affecting 
the expression of the mmpL5- mmpS5 operon as described 
for M. tuberculosis by Milano et al. [21]. PCR amplification 
and DNA sequencing of the products of the mmpL5- mmpS5 
chromosomal region in the four mutants failed to reveal 
changes in the sequence of the promoter region of mmpS5 
(MSMEG_0227) or the intergenic region of MSMEG_0226 
compared to the parental strain (data not shown).
In order to identify the mutated gene responsible for the 
azole resistance phenotype, we performed whole- genome 
sequencing of the wild- type strain (as control) and mutants 
Eco- R6 – having a generation time almost twice that of the 
parental strain – and Eco- R8 – having a generation time 
comparable to that of the parental strain – (Fig. 1). Chromo-
somal extraction, library construction and sequencing was 
conducting as described previously using an Illumina HiSeq 
2500 and 51×51 bp paired- end reads [26]. Variants including 
SNPs, insertions and deletions, were identified by alignment 
with the M. smegmatis mc2 155 reference sequence (GenBank 
accession number NC_018289.1). Analysis of the sequences 
Fig. 1. Characterization of M. smegmatis Eco- resistant mutants. Upper row: the parental strain M. smegmatis mc2155 and its derived 
spontaneous Eco- resistant mutants EcoR1, EcoR2, EcoR6 and EcoR8 were grown on 7H9- ADS- Gly agar plates supplemented with 
Congo Red dye (100 µg ml−1) for 3 days at 37 °C; colonies were observed visually and photographed with a Zeiss- Stemi 2000 lens at x2 
magnification. Lower row: sliding motility of those strains was tested by applying a 10 µl aliquot of each culture onto semi- solid M63- 
based medium and monitored after 7 days of incubation at 37 °C. Finger- like extensions appeared and spread outwards from the central 
inoculation point. The resistance to Eco and Clo of each strain was determined by plating aliquots containing ≈ 103 c.f.u. on plates of 7H9- 
GlyADS medium containing increasing concentrations of each compound and visually counting colonies after 5 days of growth at 37 °C. 
MIC
99
 was considered the drug concentration that reduced 99 % the c.f.u. counts when compared to the plates with no drug. Generation 
times for each strain were calculated from growth curves performed in 7H9ADS- Gly - 0.5 % Tw. Each experiment was done in triplicate. 
Binding of the dye Congo Red was carried out as described previously [33]. Briefly, cultures of each strain were grown at 37 °C in medium 
supplemented with Congo Red dye (100 µg ml−1) for 3 days. Cells were collected and washed, and the washed pellets were resuspended 
in acetone and Abs488 of Congo Red measured. Relative binding was calculated as OD
488
 pellet/dry weight for each mutant relative to 
the OD
488
 pellet/dry weight of the parental strain.
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obtained allowed for the identification of mutations lying on 
gene MSMEG_1915 (rshA) in both mutants; while mutant 6 
contained a T insertion at bp 246 – thus leading to a frameshift 
in the coding sequence and generating a shorter protein (83 
residues) due to a stop codon created at bp 250 – mutant 8 had 
a C55Y change at bp position 174. Of note, rshA, encoding 
an anti- sigma H protein, is present in other mycobacteria 
including M. tuberculosis, M. bovis, M. leprae and M. abscessus 
(Fig. 3a). The possible loss of function of a shortened RshA 
in mutant EcoR-6 or the loss of a critical C residue (C55) in 
mutant EcoR8 could impair RshA function and in the case of 
the latter mutant, may explain the differences in generation 
times when compared to the parental strain. No other relevant 
mutations were detected upon bioinformatics analysis of each 
sequenced genome.
The alternate sigma factor SigH of M. tuberculosis is expressed 
under heat/oxidative stress and acts as a major regulator of 
several genes, including other sigma factors and redox systems 
[27, 28]. The SigH- dependent activation of this ample stress 
response system is critical for M. tuberculosis virulence, as 
it has been shown that a sigH mutant is highly attenuated 
in the mouse model of infection [29]. SigH is transcription-
ally auto- regulated by its own promoter although at the 
post- translational level a second mechanism of regulation 
is through its cognate protein, RshA. This protein located 3′ 
of sigH– provides a direct mechanism for sensing oxidative 
stress. Both RshA and SigH are phosphorylated in vitro and 
in vivo by the serine- threonine protein kinase PknB; impor-
tantly phosphorylation of RshA takes place at a T94 residue 
in M. tuberculosis [27], residue that is lost in the truncated 
version of RshA present in mutant EcoR6. The binding of 
RshA to SigH is redox- dependent, constituting the manner 
by which SigH activity is regulated in response to oxidative 
stress [28] (Fig. 3b). Kumar et al. showed that RshA and SigH 
interact through salt bridges; with four Cys residues (out of 
the five conserved Cys present in the protein, shown in bold 
in Fig. 3a) playing an important role in the conformation of 
RshA through disulfide bond formation necessary for the 
coordination to a [Fe- S] cluster [30]. Importantly, Park et 
al. demonstrated that amino acid substitution of two of the 
cysteine residues present in RshA (C55 and C58) abrogated 
the formation of the complex between RshA and SigH [28]; 
this gives support to our identification of a C55Y mutation 
in mutant Eco- R8, which may alter that disulfide bond 
formation and hence, the complex formation. These authors 
have also suggested that the mechanism of phosphorylation- 
mediated interaction between RshA and SigH allows for 
a graded response to oxidative stress [28], thus loss of the 
reside at which phosphorylation takes place in RshA would 
most likely allow for maximum expression of SigH, which is 
convenient for the handling of the cellular oxidative stress 
caused by azoles. Under the light of that information both 
of our RshA mutants will fit into a model of resistance to 
azoles in which the M. smegmatis cell shapes its intracellular 
metabolism to face oxidative stress, maximizing the activity 
of SigH through the loss of the phosphorylation site of its 
cognate regulator RshA or through mutations close to the 
[Fe- S] cluster required for RshA conformational stability and 
activity. Finally, it is also relevant to indicate that it was previ-
ously reported that RshA is a weak binder of Zn2+ [30], which 
may explain our findings on the mild but noticeable protec-
tive effect of this cation in the MIC Eco of M. smegmatis.
Our previous work revealed that Eco treatment of M. 
tuberculosis displayed very similar changes to an untreated 
Eco- resistant strain, with higher levels of glucose-6- 
phosphate, fructose-6- phosphate, glucosamine-6- phosphate 
Fig. 2. Presence of efflux- pump inhibitors, verapamil and reserpine, does not decrease the level of resistance to Eco in the M. smegmatis 
EcoR mutants. Aliquots containing 300–500 c.f.u. of the parental strain and each of the EcoR- resistant mutants were seeded into 7H9- 
ADS- Gly plates in the absence of drugs, in the presence of Eco (50 µg ml−1) or Clo (50 µg ml−1) or in the presence of Eco or Clo (50 µg ml−1 
in each case) with the addition of verapamil (40 mg ml−1) or reserpine (12 µg ml−1). Counting of colonies in each condition was performed 
upon incubation of the plates at 37 °C for 3 days. For the sake of simplicity the results of only one mutant (EcoR 8) and one efflux- pump 
inhibitor (verapamil) are shown as all the strains behaved similarly regardless of which efflux- pump inhibitor was used.
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and mannose-6- phosphate as well as lower levels of 
N- acetylglucosamine, mannose, mannose-1- phosphate, 
inositol-1- phosphate and trehalose-6- phosphate [24]. 
Econazole treatment led to changes in the levels of glucose-
6- phosphate, fructose-6- phosphate and glucosamine-6- 
phosphate decreased in the resistant mutant strain with 
econazole treatment as opposed to the increased levels 
observed in the wild- type strain, underscoring a complex 
effect of azole drugs on the mycobacterial central metabo-
lism [24]. Other possible explanations for the effect of this 
micronutrient in the frame of our findings is that it is required 
for enzymatic function of enzymes such as fructose-1,6- 
bis- phosphate aldolase or Cu Zn SOD [31]. Thus, although 
speculative, it is possible that the mild protective effect of Zn2+ 
Fig. 3. M. smegmatis EcoR mutants 6 and 8 contain mutations in the anti- sigma H protein encoded by gene MSMEG_1915 (rshA). (a) An 
aligment of RshA proteins present in mycobacteria is shown; the conserved Cys residues are displayed in bold type and the mutations 
detected in the EcoR6 and EcoR8 mutants are shown by arrows. (b) A model proposing the effect of the loss of RshA in the resistance to 
Eco in M. smegmatis is shown. Full sized wild- type RshA is shown as an oval, EcoR 6 RshA and EcoR8 RshA are shown as a shortened 
square and a full size square to depict the possible changes in SigH- RshA interactions. Materials: all chemicals used were purchased 
pure, from commercially available sources such as Sigma Aldrich, New England Biolabs or other vendors.
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could be related to the activity of one or more enzymes of 
central mycobacterial pathways. Thus, although beyond the 
scope of the present work, research on this area is warranted.
In sum, our results report for the first time the identification 
of RshA as a novel player in resistance to azoles in mycobac-
teria. Importantly, this is also the first report linking muta-
tions in rshA to resistance to an antibiotic in M. smegmatis. 
It also raises the question of whether comparable mutations 
in the M. tuberculosis genome may happen and contribute to 
drug resistance to certain drugs, a point to address in HIV- 
Tb patients undergoing fungal infections. Of note, a very 
recent report has shown that mutations in Mycobacterium 
abscessus MAB_3542 c, encoding a RshA- like protein may be 
responsible for resistance to tigecycline [32], suggesting that 
our identification of RshA as a player in the mycobacterial 
resistance to Eco may not be specific to azoles but related in 
a general way to resistance to other antibiotics, an issue that 
should be addressed in the future.
So far, only mutations in Rv0678 and MSMEG_1915 have 
been identified mycobacteria as genes linked to azole resist-
ance but surprisingly there is no report on other genes 
involved in the mechanism of action of those compounds. The 
failure in identifying a target for azole drugs using a Ts screen 
in M. smegmatis agrees with previous attempts to identify a 
target for those drugs in M. tuberculosis suggesting that they 
may not inhibit a defined target enzyme. However, our find-
ings would allow the construction of a rshA merodiploid M. 
smegmatis strain that will be valuable for the selection of new 
azole- resistant mutants affected in other novel genes.
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